Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $946000.0.

  • Fulcrum Therapeutics' Change in Account Payables rose 21851.85% to $946000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 million, marking a year-over-year decrease of 50557.49%. This contributed to the annual value of -$1.6 million for FY2024, which is 8675.26% down from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Change in Account Payables is $946000.0, which was up 21851.85% from $244000.0 recorded in Q2 2025.
  • Fulcrum Therapeutics' Change in Account Payables' 5-year high stood at $1.2 million during Q4 2021, with a 5-year trough of -$2.7 million in Q4 2024.
  • In the last 5 years, Fulcrum Therapeutics' Change in Account Payables had a median value of $163000.0 in 2023 and averaged -$58736.8.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Change in Account Payables plummeted by 435714.29% in 2021, and later skyrocketed by 115000.0% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Change in Account Payables (Quarter) stood at $1.2 million in 2021, then fell by 23.21% to $903000.0 in 2022, then plummeted by 190.48% to -$817000.0 in 2023, then tumbled by 230.11% to -$2.7 million in 2024, then soared by 135.08% to $946000.0 in 2025.
  • Its Change in Account Payables stands at $946000.0 for Q3 2025, versus $244000.0 for Q2 2025 and $343000.0 for Q1 2025.